CureVac's Cancer Vaccine Demonstrates Promising Immune Response in Phase 1 Glioblastoma Study

CureVac's CVGBM cancer vaccine shows promising immune responses in a Phase 1 study for glioblastoma. 77% of patients exhibited antigen-specific T-cell responses, with 84% being de novo. The vaccine was generally well-tolerated, leading to the selection of a 100 µg dose for the expansion phase. Despite limited data, the results suggest the vaccine's potential in breaking immune tolerance and generating new immune responses against glioblastoma.

CureVac, a renowned biopharmaceutical company specializing in messenger RNA (mRNA) therapies, recently presented encouraging data from a Phase 1 study of its CVGBM cancer vaccine in patients with glioblastoma at the European Society for Medical Oncology (ESMO) 2024 Congress [1]. This groundbreaking research could potentially pave the way for innovative treatments in this aggressive and challenging cancer indication.

Preliminary findings from the study demonstrated that 77% of evaluable patients exhibited cancer antigen-specific T-cell responses following CVGBM monotherapy [1]. Of these responses, an impressive 84% were de novo, meaning they were generated by the CVGBM vaccination in patients who had no pre-existing T-cell activity against the encoded antigens [1]. This is particularly noteworthy because CD8+ T-cells, which primarily attack and destroy cancer cells, rely on CD4+ T-cells to coordinate the immune response and support the activity of CD8+ T-cells over time [2].

The safety and tolerability profile of CVGBM were also favorable, with most common adverse events being mild to moderate systemic reactions such as headache, fever, and chills, which resolved within 1-2 days post-injection [1]. The recommended dose for the dose expansion phase, which recently started enrollment, is 100 µg [1].

Although the data presented at ESMO are still limited, these preliminary results suggest that CVGBM has the potential to break immune tolerance and generate new immune responses against glioblastoma. This could represent a significant step forward in developing effective treatments for this highly aggressive and challenging cancer indication.

References:

[1] CureVac’s CVGBM Cancer Vaccine Induces Promising Immune Responses in Phase 1 Study in Glioblastoma Presented at the ESMO 2024 Congress. (2024, September 13). Retrieved October 10, 2024, from https://www.eqs-news.com/news/corporate/curevacs-cvgbm-cancer-vaccine-induces-promising-immune-responses-in-phase-1-study-in-glioblastoma-presented-at-the-esmo-2024-congress/2130151